Παρασκευή 9 Φεβρουαρίου 2018

Breast cancer subtype and survival by parity and time since last birth

Abstract

Background

Pregnancy affects breast cancer risk but how it affects the subtype and prognosis remain controversial. We studied the effect of parity and time since last birth on breast cancer subtype and outcome.

Patients and methods

We conducted a retrospective multivariate cohort study including all premenopausal women with early breast cancer aged ≤ 50 years (N = 1306) at diagnosis at the University Hospitals Leuven (Jan. 2000–Dec. 2009). Primary study endpoints were the breast cancer subtype, disease-free survival, and distant disease-free survival by parity and time since last birth. Statistical methods used were baseline-category logits models and Cox proportional hazard models. Multivariable models were used to correct for possible confounders.

Results

Breast cancer subtypes did not differ between nulliparous (N = 266) and parous women (N = 1040) but subtypes differed significantly in parous women by time since last birth (p < 0.001). Tumors within 5 years of last birth were proportionally more likely triple negative and HER-2 like, even when corrected for age at diagnosis. After a mean follow-up period of 10 years, parous women had a better disease-free survival compared to nulliparous women (HR 0.733; CI 0.560–0.961; p = 0.025, HR 0.738; CI 0.559–0.974; p = 0.032 before and after correction for known prognostic factors, respectively). In parous women, a longer time since last birth was correlated with a longer disease-free survival compared to patients with a recent pregnancy (HR 0.976; CI 0.957–0.996; p = 0.018). However, after correction, this association completely disappeared (HR 1.010; CI 0.982–1.040; p = 0.480).

Conclusion

We observed a better disease-free survival for parous than nulliparous women. The influence of recent birth on disease-free survival is probably due to tumor and patient characteristics, as recent birth is associated with more aggressive subtypes.



http://ift.tt/2nXi53R

Measuring Development of Adolescent and Young Adult Cancer Patients: An Integrative Review of Available Instruments

Journal of Adolescent and Young Adult Oncology , Vol. 0, No. 0.


from Cancer via ola Kala on Inoreader http://ift.tt/2H3mP0x
via IFTTT

Measuring Development of Adolescent and Young Adult Cancer Patients: An Integrative Review of Available Instruments

Journal of Adolescent and Young Adult Oncology , Vol. 0, No. 0.


http://ift.tt/2H3mP0x

The challenges of fertility preservation in cancer patients: an interview with Michael Grynberg

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2Ef0qQ2
via IFTTT

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2CaEJe1
via IFTTT

Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2EhhtAS
via IFTTT

A multiparametric analysis combining DCE-MRI- and IVIM -derived parameters to improve differentiation of parotid tumors: a pilot study

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2CaWzOa
via IFTTT